# A Study on the Control of Chronic Obstructive Pulmonary Disease (COPD) in Patients Taking the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler

> **NCT03663569** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 4819 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Spiolto® Respimat®

## Key facts

- **NCT ID:** NCT03663569
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-15
- **Primary completion:** 2019-10-04
- **Final completion:** 2019-10-04
- **Target enrollment:** 4819 (ACTUAL)
- **Last updated:** 2025-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03663569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03663569, "A Study on the Control of Chronic Obstructive Pulmonary Disease (COPD) in Patients Taking the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03663569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*